Brief: Lundbeck, Takeda Modify Collaboration Agreement For Trintellix In U.S.
July 31 (Reuters) - H Lundbeck A/S HLUNb.CO :
* LUNDBECK AND TAKEDA MODIFY COLLABORATION AGREEMENT FOR
TRINTELLIX IN U.S.
* H LUNDBECK A/S WILL CEASE ALL PROMOTIONAL EFFORTS FOR
TRINTELLIX
(VORTIOXETINE) IN U.S.
* H LUNDBECK A/S WILL RECEIVE A FIXED, UNDISCLOSED ROYALTY
RATE
BASED ON NET SALES IN U.S. FOR 2025 AND 2026.
* AGREEMENT IS EXPECTED TO HAVE ONLY A LIMITED IMPACT ON
REVENUE
AND ADJUSTED EBITDA
Further company coverage: HLUNb.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on H Lundbeck A/S
See all newsUBS upgrades Lundbeck to 'buy' on high epilepsy drug conviction
DB downgrades Lundbeck to 'sell' on Rexulti patent cliff risk
Europe Research Roundup: ASM International, Michelin, Nokian Renkaat
Europe Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program